This Week in Addiction Medicine from ASAM cover art

All Episodes

This Week in Addiction Medicine from ASAM — 102 episodes

#
Title
1

Lead: Access to medications for opioid use disorder among veterans with homeless experience in permanent supportive housing

2

Lead: Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements

3

Lead: Outpatient Direct Initiation of Injectable Buprenorphine in a Harm Reduction Agency and Primary Care Clinic: A Retrospective Case Series

4

Lead: A µ-opioid receptor superagonist analgesic with minimal adverse effects

5

Lead: Methadone Dose and Patient-Directed Discharge in Hospitalized Patients with Opioid Use Disorder

6

Lead: Do US Adults View Drug and Alcohol Addiction as a Health Condition?

7

Lead: Cannabis cessation and neurocognitive recovery: Patterns, predictors, and clinical implications—a systematic review

8

Lead: Cost-effectiveness of contingency management for methamphetamine use disorder: A model-based analysis

9

Lead: Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study

10

Lead: Does the total consumption model apply to cannabis use?

11

Lead: Spirituality and Harmful or Hazardous Alcohol and Other Drug Use

12

Lead: Emergency Department–Initiated Buprenorphine for Opioid Use Disorder

13

Lead: Use of gabapentin with or without a prescription in substance use treatment settings: A national analysis of urine drug testing data, 2016–2023

14

Lead: Association of alcohol intake over the lifetime with colorectal adenoma and colorectal cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

15

Lead: Medication Availability for Alcohol Use Disorder in Substance Use Disorder Treatment Facilities

16

Lead: Public Views About Opioid Overdose and People With Opioid Use Disorder

17

Lead: Did the illicit fentanyl trade experience a supply shock?

18

Lead: Barriers to Buprenorphine Initiation in Patients Using Fentanyl

19

Lead: Productivity Losses From Substance Use Disorder in the U.S. in 2023

20

Lead: Expanding Access to Buprenorphine and Methadone: Global Perspectives and Policy Recommendations

21

Lead: Very Low Nicotine Content Cigarettes for Smoking Cessation: Examining a Facilitated Extinction Approach and Dosing Schedule

22

Lead: Fatal Opioid Overdoses by Historical and Contemporary Neighborhood-Level Structural Racism

23

Lead: State Laws Banning Prior Authorization For Medications For Opioid Use Disorder Increased Substantially, 2015–23

24

Lead: Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine

25

Lead: States With Substantial Increases In Buprenorphine Uptake Did So With Increased Medicaid Prescribing, 2018–24

26

Lead: Ultra-processed food addiction in a nationally representative sample of older adults in the USA

27

Lead: Alcohol Consumption Per Capita and Suicide: A Meta-Analysis

28

Lead: Measures of General Intelligence and Risk for Alcohol Use Disorder

29

Lead: Medications for Opioid Use Disorder Playbook

30

Lead: Cannabis Use During Pregnancy and Lactation

31

Lead: Contingency Management for Stimulant Use Disorder and Association With Mortality: A Cohort Study

32

Lead: Machine learning– and multilayer molecular network–assisted screening hunts fentanyl compound

33

Lead: Evaluation of a Novel Patient-Centered Methadone Restart Protocol

34

Lead: Recommendations for Addressing In-Hospital Substance Use From a National Delphi Consensus Process

35

Lead: Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting

36

Lead: Association between housing status and mental health and substance use severity among individuals with opioid use disorder and co-occurring depression and/or PTSD

37

Lead: Oral methadone versus sublingual buprenorphine for the treatment of acute opioid withdrawal: A triple-blind, double-dummy, randomized control trial

38

Lead: Implementation Gaps in US Syringe Service Programs, 2022

39

Lead: Co-involvement of stimulants with opioids in North America: A 'silent epidemic’

40

Lead: Did alcohol facilitate the evolution of complex societies?

41

Lead: Disparities in Treatment and Referral After an Opioid Overdose Among Emergency Department Patients

42

Lead: Prescriber-Level Changes in Buprenorphine Dispensing in the USA Before and After Federal Policy Changes Aimed at Increasing Prescribing

43

Lead: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits

44

Lead: Receipt of addiction treatment after nonfatal opioid overdose and risk of subsequent overdose: A retrospective cohort study

45

Lead: Bitter sensing protects Drosophila from developing experience-dependent cocaine consumption preference

46

Lead: Memory function in patients with opioid dependence treated with buprenorphine and methadone in comparison with healthy persons

47

Lead: Medicaid Unwinding and Changes in Buprenorphine Dispensing

48

Lead: Loneliness Among US Veterans With Problematic Substance Use: Results From the National Health and Resilience in Veterans Study

49

Lead: The IARC Perspective on the Effects of Policies on Reducing Alcohol Consumption

50

Lead: Building Multidisciplinary Consensus on Inpatient Xylazine Management through Clinical Protocols

51

Lead: Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial

52

Lead: Comprehensive drug policies increase trust in local government: an analysis of authorities’ and residents’ perspectives in rural US Appalachian and Midwestern counties

53

Lead: Hospital Addiction Consultation Service and Opioid Use Disorder Treatment

54

Lead: Averted lung cancer deaths due to reductions in cigarette smoking in the United States, 1970–2022

55

Lead: Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years

56

Lead: Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans

57

Lead: Association Between Telehealth Initiation Of Stimulant Therapy And New Substance Use Disorder Diagnoses

58

Lead: The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021

59

Lead: Illicit Substance Use and Treatment Access Among Adults Experiencing Homelessness

60

Lead: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder

61

Lead: Cannabis Use Disorder Emergency Department Visits and Hospitalizations and 5-Year Mortality

62

Lead: Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive Disorders

63

Lead: Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl

64

Lead: Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis Poisoning

65

Lead: Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice

66

ASAM Weekly Special Episode: Dr. David Fiellin & Dr. Eric Strain sit down to discuss the concept of Treatment Refractory Addiction

67

Lead: Review of Evidence on Alcohol and Health

68

Lead: The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies

69

Lead: Prevalence of pharmacotherapy for attention-deficit/hyperactivity disorder and prescription stimulant misuse: A national study of US college students

70

Lead: Xylazine Pharmacokinetics in Patients Testing Positive for Fentanyl and Xylazine

71

Lead: Suicide in people prescribed opioid-agonist therapy in Scotland, United Kingdom, 2011–2020: A national retrospective cohort study

72

Lead: Links between adolescent binge drinking and midlife alcohol use behaviors by age, sex, and race/ethnicity

73

Lead: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder

74

Lead: Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization

75

Lead: Facilitators of and barriers to buprenorphine initiation in the emergency department: a scoping review

76

Lead: Cannabis Policy Impacts Public Health and Health Equity

77

ASAM Weekly Special Episode: Dr. Shannon Miller talks PAM-7 and his path to addiction medicine [From the ASAM 55th Annual Conference]

78

Lead: Risk of Incident Psychosis and Mania With Prescription Amphetamines

79

Lead: Cannabis Laws and Utilization of Medications for the Treatment of Mental Health Disorders

80

Lead: State-level racial and ethnic disparities in buprenorphine treatment duration in the United States

81

Lead: Virtual reality-based Mindfulness-Oriented Recovery Enhancement (MORE-VR) as an adjunct to medications for opioid use disorder: a Phase 1 trial

82

Lead: The Lancet Psychiatry Commission on youth mental health

83

Lead: Alcohol Consumption Patterns and Mortality Among Older Adults With Health-Related or Socioeconomic Risk Factors

84

Lead: Physician Reluctance to Intervene in Addiction: A Systematic Review

85

ASAM Weekly Special Episode: Rapid Initiation of Injection Naltrexone for OUD | Dr. Matisyahu Shulman & Dr. Adam Bisaga

86

Lead: Social Vulnerability and Prevalence and Treatment for Mental Health and Substance Use Disorders

87

Lead: Psilocybin desynchronizes the human brain

88

Lead: Secondhand Nicotine Absorption From E-Cigarette Vapor vs Tobacco Smoke in Children

89

Lead: Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration: a population-based study

90

Lead: Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial

91

Lead: Global status report on alcohol and health and treatment of substance use disorders

92

Lead: Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths

93

Lead: Piloting a Hospital-Based Rapid Methadone Initiation Protocol for Fentanyl

94

Lead: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population

95

Lead: Innovation and adaptation: The rise of a fentanyl smoking culture in San Francisco

96

Lead: Rapid Initiation of Injection Naltrexone for Opioid Use Disorder

97

Lead: Burden of Mental Disorders and Suicide Attributable to Childhood Maltreatment

98

Lead: Associations of cannabis use, use frequency, and cannabis use disorder with violent behavior among young adults in the United States

99

Lead: Biomarkers of metal exposure in adolescent e-cigarette users

100

Lead: Association of regular opioid use with incident dementia and neuroimaging markers of brain health in chronic pain patients

101

Lead: Preventing deaths after prison release

102

Lead: Telling the story of the opioid crisis